SCHEMBL633760

SCHEMBL633760

CCCCCCCCCCCCC(C)N

nearest known ligand 0.94

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.94
TP53 P04637 2/20 0.70
SPHK1 Q9NYA1 2/20 0.58
CYP2D6 P10635 2/20 0.48
LMNA P02545 2/20 0.48
LAP3 P28838 2/20 0.48
PLA2G1B P04054 1/20 0.48
PLA2G2A P14555 1/20 0.48
GMNN O75496 1/20 0.48
POLB P06746 1/20 0.48
THPO P40225 1/20 0.48
MTOR P42345 1/20 0.48
BLM P54132 1/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CETP P11597 1/20 0.48
HTT P42858 1/20 0.48
UBE2N P61088 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14294046 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA
SCHEMBL2365616 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA
SCHEMBL16366968 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA
SCHEMBL37106 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA
SCHEMBL20495958 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA
SCHEMBL20495969 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA
SCHEMBL20495963 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA
SCHEMBL20495967 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA
SCHEMBL20495961 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA
SCHEMBL20820762 1.00 OPRM1 (0.94) OPRM1TP53SPHK1CYP2D6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3189053-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF UNICHEM LAB LTD (IN) 2021-05-05 EP claimed
EP-3617243-A1 METHOD FOR THE PRODUCTION OF POLYISOCYANATES COMPRISING ISOCYANURATE GROUPS AND THEIR USE BASF SE (DE) 2020-03-04 EP claimed
EP-2760814-B1 PROCESSES FOR SEPARATING COMPONENTS IN ALKYL PERFLUOROALKENE ETHER PRODUCTION DU PONT (US) 2015-10-28 EP claimed
EP-1319040-B1 POLYMER-ORGANOCLAY COMPOSITE COMPOSITIONS, METHOD FOR MAKING AND ARTICLES THEREFROM SABIC INNOVATIVE PLASTICS IP (NL) 2014-08-20 EP claimed
EP-2072499-B1 Method for manufacturing thiodiglycolic dialkyl esters SALTIGO GMBH (DE) 2012-02-22 EP claimed
JP-4750278-B2 2011-08-17 JP claimed
EP-1848702-A2 PRO-FRAGRANCE AND PRO-FLAVORANT COMPOSITIONS Flexitral, Inc. (US) 2007-10-31 EP claimed
WO-2006085048-A2 PRO-FRAGRANCE AND PRO-FLAVORANT COMPOSITIONS FLEXITRAL, INC. (US) 2006-08-17 WO claimed
EP-1140054-B1 BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS BACANER MARVIN B (US) 2005-03-16 EP claimed
EP-1390032-A4 NOVEL QUATERNARY AMMONIUM COMPOSITIONS COUPLED WITH FACILITATING ANIONS AND THEIR USE IN KITS, AS WELL AS THEIR USE IN PREVENTING AND TREATING CERTAIN CONDITIONS BACANER MARVIN B (US) 2004-12-29 EP claimed
US-20030065015-A1 Novel quarternary ammonium compositions coupled with facilitating anions and their use in kits, as well as their use in preventing and treating certain conditions BACANER MARVIN B (US) 2003-04-03 US claimed
WO-2002092003-A2 NOVEL THERAPEUTICAL QUATERNARY AMMONIUM COMPOSITIONS BACANER MARVIN B (US) 2002-11-21 WO claimed
US-6482811-B1 Bretylium compositions and kits, and their use in preventing and treating cardio-vascular conditions BACANER MARVIN B (US) 2002-11-19 US claimed
US-6423768-B1 MIXTURES CONTAINING POLYAMIDES, POLYPHENYLENE ETHER AND IMPACT STRENGTH ADJUVANTS GENERAL ELECTRIC COMPANY 2002-07-23 US claimed
WO-2002022729-A1 POLYMER-ORGANOCLAY COMPOSITE COMPOSITIONS, METHOD FOR MAKING AND ARTICLES THEREFROM GENERAL ELECTRIC COMPANY (US) 2002-03-21 WO claimed
EP-1140054-A2 BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS Bacaner, Marvin B. (US) 2001-10-10 EP claimed
WO-2000040232-A2 BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS BACANER MARVIN B (US) 2000-07-13 WO claimed
EP-0526401-B1 Process for the preparation of glycidyl ethers of di-secondary alcohols with high monomer content CIBA GEIGY AG (CH) 1994-12-28 EP claimed
US-4430513-A COBALT OR RHODIUM CARBONYL, CARBON-CARBON BOND FORMATION UOP INC. (US) 1984-02-07 US claimed
US-4196151-A Process for producing β,γ-unsaturated aldehyde NIPPON OIL AND FATS CO., LTD. (JP) 1980-04-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065015-A1 Novel quarternary ammonium compositions coupled with facilitating anions and their use in kits, as well as their use in preventing and treating certain conditions SLC10A1, ATP6V1B1, SLC7A1 OPRM1 3335/4885TP53 3326/4885SPHK1 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.